Page 1 of 2

Metastatic renal-cell carcinoma: switch to metronomic chemotherapy could offer new treatment option

A new multi-targeted chemo-switch drug regimen shows promising anti-tumour activity with manageable side effects in patients with metastatic renal-cell carcinoma ( RCC ), a disease with few treatment options. Combining maximum tolerated dose ( MTD ) chemotherapy ( Gemcitabine; Gemzar ) with metronom...
Read Article

Advanced kidney cancer: Sunitinib shows promising results in patients with poor prognosis

Sunitinib ( Sutent ) prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer ( metastatic renal cell carcinoma ) patients with a poor prognosis such as the elderly and those whose cancer has spread to the brain. Sunitinib is an oral targeted drug t...
Read Article

Advanced kidney cancer: Sunitinib shows promising results in patients with poor prognosis

Sunitinib ( Sutent ) prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer ( metastatic renal cell carcinoma ) patients with a poor prognosis such as the elderly and those whose cancer has spread to the brain. Sunitinib is an oral targeted drug t...
Read Article

Severe hypersensitivity reactions during infusion of Temsirolimus

Temsirolimus (Torisel ) is an antineoplastic agent used to treat patients with advanced renal-cell carcinoma who have at least three of six prognostic risk factors. Infusion-related hypersensitivity reactions have occurred during the administration of Temsirolimus. The reactions include, but are no...
Read Article

Advanced form of kidney cancer: Votrient approved

The FDA ( Food and Drug Administration ) has approved Votrient ( Pazopanib ), the sixth drug to be approved for kidney cancer since 2005. Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. Votrient is i...
Read Article

Sorafenib: older renal cancer patients appear to benefit from treatment

Older and younger patients with renal cancer derive similar benefit from Sorafenib ( Nexavar ) therapy and tolerate the drug equally well. Although the risk of being diagnosed with cancer increases with age, relatively few older patients participate in clinical trials. There is a general percept...
Read Article

Treatment with RAD001 increases time without tumour growth in patients with advanced kidney cancer

Updated study findings from the RECORD-1 ( REnal Cell cancer treatment with Oral RAD001 given Daily ) study have shown that patients with advanced kidney cancer receiving RAD001 had no tumour growth for nearly 5 months versus 1.9 months for patients receiving placebo ( hazard ratio = 0.33; p< 0.001 ...
Read Article

Sorafenib targets acute myeloid leukemia driven by mutant FLT3 gene

A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia ( AML ), the most common and lethal form of adult leukemia, researchers at The University of Texas M. D. Anderson Cancer Center reported in the Journal of the National...
Read Article

FDA has approved Nexavar for patients with inoperable hepatocellular carcinoma

The FDA ( Food and Drug Administration ) has approved Nexavar ( Sorafenib ) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a ...
Read Article

Nexavar significantly extends overall survival in hepatocellular carcinoma patients

Sorafenib ( Nexavar ) tablets has significantly extended overall survival in patients with hepatocellular carcinoma ( HCC ), or primary liver cancer versus those taking placebo by 44% ( HR=0.69; p-value=0.0006 ). The Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol ( SHARP...
Read Article